Linking rational design and material-sparing strategies for enabled intermediates and their drug products.

The identification of the unique risks to oral bioavailability is critical for identifying appropriate enabled forms and formulations.

Register Free: https://www.pharmtech.com/pt_w/amorphous-solid-dispersions

Event Overview:

The rapid development of enabled forms and formulations is essential if the challenges posed by poorly soluble molecules entering the development pipeline are to be overcome. The identification of the unique risks to oral bioavailability is critical for identifying appropriate enabled forms and formulations. The webcast will describe some of the material-sparing techniques used at Lonza. These include:

• Small-scale spray drying
• Compaction simulation
• ASAP Prime
• Physiologically based pharmacokinetic (PBPK) modeling
• Salt/co-crystal creation

Key Learning Objectives:

• Gain insight into how Lonza’s formulation development process can improve bioavailability
• Learn about the advantages of material-sparing formulation
• Discover how excipient compatibility and drug product formulation can be explored together via compaction simulation and other modeling tools

Who Should Attend:

• Scientists involved in Drug Formulation and metabolism; Pharmacokinetics; and Physiologically based Pharmacokinetics Modeling.
• Chemistry, Manufacturing, and Controls colleagues looking for rapid formulation screening methodologies.
• Experts in Solid Form, Amorphous Solid Dispersion, and Solid Dosage Forms who want to learn more about Early Formulation Screening.

Speakers

Hannah Worrest
Manager, Bioavailability Enhancement Engineering
Lonza Small Molecules

Hannah Worrest is a Manager in Bioavailability Enhancement (Product Development). Hannah leads a group of spray drying engineers dedicated to the success of clinical and commercial manufacturing. Additionally, she drives initiatives aimed at improving the use of historical data to build predictive models for spray drying processes such as the particle size prediction application of the Lonza spray drying thermo model. Worrest received her bachelor’s degree in chemical engineering from Montana State University.

Bailey Coker, MEng
Bioavailability Enhancement Engineer
Lonza Small Molecules

Bailey Coker, MEng, is an engineer specializing in Bioavailability Enhancement within product development. As the engineering lead on clinical programs for both spray-dried dispersions and solid dosage forms, she plays a pivotal role in advancing innovative solutions. Her expertise is centered on the scale-up and technology transfer processes for early-phase clinical initiatives, ensuring seamless transitions from development to clinical manufacture. Bailey holds a bachelor’s degree in Chemical Engineering and a master’s degree in Biomedical Engineering from Colorado State University.

Dr. Allison DuRoss
Manager, Bioavailability Enhancement Engineering
Lonza Small Molecules

Dr.DuRoss is a Manager in Bioavailability Enhancement (Product Development). Allison leads a group of solid dosage engineers dedicated to the success of clinical and commercial manufacturing. Additionally, she supports innovation and integration of new technologies into product development. Most recently, she worked with the solid dosage team to redefine the feasibility and scale-up offering at Lonza improving formulations and processes through the capabilities of the Styl’One Evo compaction simulator. She received her B.S.E. in Chemical Engineering from the University of Michigan and Ph.D. in Pharmaceutical Sciences from Oregon State University.

Register Free: https://www.pharmtech.com/pt_w/amorphous-solid-dispersions